PhaseV
United States
- Boston, Massachusetts
- 25/10/2023
- Unknown
- $15,000,000
PhaseV is leveraging cutting-edge algorithms such as reinforcement learning and causal ML for adaptive trial design and closed-loop execution, in order to improve trial success rate while maximizing resource and time efficiency. Our novel methodology and advanced technology also enable the detection of hidden signals in data while analyzing clinical trial results and extracting actionable insights.
- Industry Pharmaceutical Manufacturing
- Website https://phasevtrials.com/
- LinkedIn https://www.linkedin.com/company/phasevtrials/about/
Related People
Raviv PrylukCo Founder
Israel -
Tel Aviv-Yafo, Tel Aviv District
Experienced executive & leader of technology and operations teams. A passion for solving complex multidisciplinary problems in a data-driven and results-oriented manner for making a broad and positive impact in the world. Long track record of excellence across several fields and industries - engineering, machine learning, data science, biotechnology, computational neuroscience (Ph.D.), and more.
Syntracts | $5,300,000 | (Oct 24, 2025)
GradBridge | $20,000,000 | (Oct 24, 2025)
Sumble | $38,500,000 | (Oct 24, 2025)
CipherOwl | $15,000,000 | (Oct 24, 2025)
Sizable Energy | $8,000,000 | (Oct 24, 2025)
Elevara Medicines | $70,000,000 | (Oct 24, 2025)
Vermeer | $10,000,000 | (Oct 24, 2025)
GammaTime | $14,000,000 | (Oct 24, 2025)
Cybrid | $10,000,000 | (Oct 24, 2025)
Apriority Financial, Inc. | $2,300,000 | (Oct 24, 2025)
OneAM | $4,700,000 | (Oct 24, 2025)
🌱 Rightcharge | $2,131,920 | (Oct 24, 2025)
Tensormesh | $4,500,000 | (Oct 24, 2025)